LEADER 04056nam 2200457z- 450 001 9910261141903321 005 20210211 035 $a(CKB)4100000002484673 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/56127 035 $a(oapen)doab56127 035 $a(EXLCZ)994100000002484673 100 $a20202102d2017 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPhage Therapy: Past; Present and Future 210 $cFrontiers Media SA$d2017 215 $a1 online resource (392 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88945-251-4 330 $aHistorically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d'He?relle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic. 517 $aPhage Therapy 606 $aMicrobiology (non-medical)$2bicssc 610 $abacterial infection treatment 610 $abacteriophage therapy 610 $abiocontrol 610 $abiofilms 610 $aimmunology 610 $alysins 610 $aregulatory issues 615 7$aMicrobiology (non-medical) 700 $aAbedon$b Stephen T$4auth$01239822 702 $aGarcia$b Pilar$4auth 702 $aAminov$b Rustam$4auth 702 $aMullany$b Peter$f1959-$4auth 906 $aBOOK 912 $a9910261141903321 996 $aPhage Therapy: Past; Present and Future$93855566 997 $aUNINA LEADER 02784nas 2200637-a 450 001 9910171060003321 005 20240913213023.0 035 $a(DE-599)ZDB2170918-X 035 $a(CKB)110978977118258 035 $a(CONSER)---50028053- 035 $a(EXLCZ)99110978977118258 100 $a20760403b19462011 --- b 101 0 $ager 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAussenwirtschaft $eZeitschrift für internationale Wirtschaftsbeziehungen /$fherausgegeben vom Schweizerischen Institut für Aussenwirtschafts- und Marktforschung an der Handels-Hochschule St. Gallen 210 $aBern $cA. Francke$d[1946]- 215 $a1 online resource 300 $aRefereed/Peer-reviewed 300 $aTitle from cover. 300 $aOther title information varies. 300 $aImprint varies. 300 $aVolumes for <1991-> have also English title: The Swiss review of international economic relations. 311 08$aPrint version: Aussenwirtschaft : 0004-8216 517 1 $aAussen-Wirtschaft 517 3 $aSwiss review of international economic relations 531 $aAUSSENWIRTSCHAFT SWISS REVIEW OF INTERNATIONAL ECONOMIC RELATIONS 531 $aAUSSENWIRTSCHAFT 531 0 $aAussenwirtschaft 606 $aCommerce$vPeriodicals 606 $aCommerce international$2eclas 606 $aPublications périodiques$2eclas 606 $aRelations économiques internationales$2eclas 606 $aCommerce$2fast$3(OCoLC)fst00869279 606 $aInternationale economische betrekkingen$2gtt 607 $aSwitzerland$xCommerce$vPeriodicals 607 $aSwitzerland$2fast$1https://id.oclc.org/worldcat/entity/E39QbtfRmBCgpQrWH3VGcB88Pp 608 $aPeriodicals.$2fast 608 $aPeriodicals.$2lcgft 615 0$aCommerce 615 7$aCommerce international. 615 7$aPublications périodiques. 615 7$aRelations économiques internationales. 615 7$aCommerce. 615 17$aInternationale economische betrekkingen. 676 $a382.05 712 02$aHandels-Hochschule St. Gallen.$bSchweizerisches Institut fu?r Aussenwirtschafts- und Marktforschung. 712 02$aHochschule St. Gallen fu?r Wirtschafts- und Sozialwissenschaften.$bSchweizerisches Institut fu?r Aussenwirtschafts- und Marktforschung. 712 02$aHochschule St. Gallen fu?r Wirtschafts- und Sozialwissenschaften.$bSchweizerisches Institut fu?r Aussenwirtschafts-, Struktur- und Marktforschung. 712 02$aUniversita?t St. Gallen.$bSchweizerisches Institut fu?r Aussenwirtschaft und Angewandte Wirtschaftsforschung. 906 $aJOURNAL 912 $a9910171060003321 920 $aexl_impl conversion 996 $aAussenwirtschaft$92285827 997 $aUNINA